Eurofins Scientific (ERF) Stock Overview
Provides various analytical testing and laboratory services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ERF Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Eurofins Scientific SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €68.46 |
| 52 Week High | €74.32 |
| 52 Week Low | €45.56 |
| Beta | 0.96 |
| 1 Month Change | -0.49% |
| 3 Month Change | 17.47% |
| 1 Year Change | 33.92% |
| 3 Year Change | 0.32% |
| 5 Year Change | -16.31% |
| Change since IPO | 28,668.33% |
Recent News & Updates
Recent updates
Investors Appear Satisfied With Eurofins Scientific SE's (EPA:ERF) Prospects As Shares Rocket 27%
Jan 14
Is Eurofins Scientific SE (EPA:ERF) Trading At A 36% Discount?
Nov 23These 4 Measures Indicate That Eurofins Scientific (EPA:ERF) Is Using Debt Reasonably Well
Nov 02Eurofins Scientific SE's (EPA:ERF) Price In Tune With Earnings
Aug 14Eurofins Scientific SE (EPA:ERF) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Jul 26Eurofins Scientific (EPA:ERF) Has A Pretty Healthy Balance Sheet
Jun 02Is There Now An Opportunity In Eurofins Scientific SE (EPA:ERF)?
Apr 28Shareholders Should Be Pleased With Eurofins Scientific SE's (EPA:ERF) Price
Apr 10Does Eurofins Scientific (EPA:ERF) Have A Healthy Balance Sheet?
Mar 01Eurofins Scientific's (EPA:ERF) Earnings May Just Be The Starting Point
Feb 07
Digital Initiatives And Lab Expansion Set To Transform Operations By 2027
Long-term investments in CapEx and digitalization are expected to enhance future revenue, improve net margins, and boost earnings.Shareholder Returns
| ERF | FR Life Sciences | FR Market | |
|---|---|---|---|
| 7D | 3.4% | -4.3% | 1.6% |
| 1Y | 33.9% | -10.5% | 1.5% |
Return vs Industry: ERF exceeded the French Life Sciences industry which returned -10.5% over the past year.
Return vs Market: ERF exceeded the French Market which returned 1.5% over the past year.
Price Volatility
| ERF volatility | |
|---|---|
| ERF Average Weekly Movement | 4.0% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 11.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ERF has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ERF's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 65,000 | Gilles Martin | www.eurofins.com |
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, training, advisory, and labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services.
Eurofins Scientific SE Fundamentals Summary
| ERF fundamental statistics | |
|---|---|
| Market cap | €11.98b |
| Earnings (TTM) | €416.00m |
| Revenue (TTM) | €7.30b |
Is ERF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERF income statement (TTM) | |
|---|---|
| Revenue | €7.30b |
| Cost of Revenue | €5.66b |
| Gross Profit | €1.64b |
| Other Expenses | €1.23b |
| Earnings | €416.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.36 |
| Gross Margin | 22.49% |
| Net Profit Margin | 5.70% |
| Debt/Equity Ratio | 96.9% |
How did ERF perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/05 18:20 |
| End of Day Share Price | 2026/02/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eurofins Scientific SE is covered by 32 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hubert D'Aillieres | Banco BPI, S.A. |
| James Rosenthal | Barclays |
| James Rowland Clark | Barclays |